Iterum Therapeutics Valuation
| ITRM Stock | USD 2.39 0.15 6.70% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Iterum Therapeutics PLC retains a regular Real Value of $1.42 per share. The prevalent price of the firm is $2.39. Our model calculates the value of Iterum Therapeutics PLC from evaluating the firm fundamentals such as Shares Owned By Insiders of 1.81 %, return on asset of -0.73, and Return On Equity of -5.56 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Iterum Therapeutics' valuation include:
Price Book 6.0287 | Enterprise Value 73.7 M | Enterprise Value Ebitda 0.5453 | Price Sales 1.3 K | Enterprise Value Revenue 105.2207 |
Overvalued
Today
Please note that Iterum Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Iterum Therapeutics PLC is based on 3 months time horizon. Increasing Iterum Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Iterum stock is determined by what a typical buyer is willing to pay for full or partial control of Iterum Therapeutics PLC. Since Iterum Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Iterum Stock. However, Iterum Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.39 | Real 1.42 | Target 1.0 | Hype 3.22 | Naive 2.63 |
The intrinsic value of Iterum Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Iterum Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Iterum Therapeutics PLC helps investors to forecast how Iterum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Iterum Therapeutics more accurately as focusing exclusively on Iterum Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Iterum Therapeutics' intrinsic value based on its ongoing forecasts of Iterum Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Iterum Therapeutics' closest peers.
Iterum Therapeutics Cash |
|
Iterum Valuation Trend
Knowing Iterum Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Iterum Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Iterum Therapeutics Total Value Analysis
Iterum Therapeutics PLC is currently projected to have valuation of 73.7 M with market capitalization of 61.64 M, debt of 18.96 M, and cash on hands of 68.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Iterum Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
73.7 M | 61.64 M | 18.96 M | 68.91 M |
Iterum Therapeutics Asset Utilization
One of the ways to look at asset utilization of Iterum is to check how much profit was generated for every dollar of assets it reports. Iterum Therapeutics retains a negative application of resources of -0.73 (percent), losing $0.007335 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Iterum Therapeutics PLC shows how discouraging it operates for each dollar spent on its resources.Iterum Therapeutics Ownership Allocation
Iterum Therapeutics PLC has a total of 27.52 Million outstanding shares. Roughly 89.21 (percent) of Iterum Therapeutics outstanding shares are held by general public with 1.81 % owned by insiders and only 8.98 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Iterum Therapeutics Profitability Analysis
Net Loss for the year was (38.37 M) with profit before overhead, payroll, taxes, and interest of 37 K.About Iterum Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Iterum Therapeutics PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Iterum Therapeutics PLC based exclusively on its fundamental and basic technical indicators. By analyzing Iterum Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Iterum Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Iterum Therapeutics. We calculate exposure to Iterum Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Iterum Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1.8 M | -1.7 M | |
| Pretax Profit Margin | -3.2 K | -3 K | |
| Operating Profit Margin | -3.2 K | -3 K | |
| Net Loss | -3.2 K | -3 K |
Iterum Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Iterum Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13 M |
Iterum Therapeutics Current Valuation Indicators
Iterum Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Iterum Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Iterum Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Iterum Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Iterum Therapeutics' worth.When determining whether Iterum Therapeutics PLC is a strong investment it is important to analyze Iterum Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iterum Therapeutics' future performance. For an informed investment choice regarding Iterum Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.